Seer Inc

seer.bio

What Do They Do?

Sells a proteomics platform of consumable assays, automation instruments and data-analysis software to academic and commercial researchers, including biopharmaceutical companies, biobanks and clinical research organizations.

How Do They Make Money?

Customers pay for the instrument and consumables when shipped, and for proteomic-data generation and analysis when the report is delivered; invoices are generally due within 30 or 60 days.

FY2025 revenue

Who Are Their Customers?

Organizations conducting research buy Seer’s products and services; Seer sells directly in the United States and through direct sales and distributors outside the United States.

Do Revenues Turn Into Profits?

No. It lost $73.6M in FY2025.

Operating income, FY2025

−470% of revenue

▼ −22% (Loss) vs FY2024 (−$100.1M, −706%)

Net income, FY2025

−444% of revenue

▼ −15% (Loss) vs FY2024 (−$86.6M, −611%)

Free cash flow, FY2025

−279% of revenue

▼ −7% (Loss) vs FY2024 (−$49.7M, −351%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −23%; vs $4.1M in Q2 FY2025
Net income: ▼ −13% (Loss); vs −$19.4M in Q2 FY2025

Aug 11, 2026 Seer reaffirms its full-year revenue outlook It expects 2026 revenue of $16 million to $18 million, with 3% growth at the midpoint over 2025.
Jul 31, 2026 Seer receives two revised acquisition proposals for its shares One proposal came from the Radoff-JEC Group and one from CEO Omid Farokhzad.

Growing. Revenue grew 2.5x in 4 years, from $6.6M in FY2021 to $16.6M in FY2025, about 26% a year.

Proteograph assay update The product offering expands to include the Proteograph ONE assay, alongside the integrated consumables, instrument and software suite described in the older report.

Who Do They Compete With?

Competes with Agilent Technologies, Bio-Techne, Bruker, Danaher, DiaSorin, Illumina, Thermo Fisher Scientific, Alamar Biosciences, Nautilus Biotechnology, Quanterix, and Quantum-Si

Comments